Results 141 to 150 of about 739,569 (400)

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Long non-coding RNA DANCR, a prognostic indicator, promotes cell growth and tumorigenicity in gastric cancer

Tumor Biology, 2017
Gastric cancer remains the third leading cause of cancer-related mortality worldwide, and proliferation of gastric cancer represents the major reason for its poor prognosis.
Yan-Ping Hao, Jing-Hui Qiu, Dong-Bo Zhang, Cheng-Gong Yu   +3 more
doaj   +1 more source

Immune-related long non-coding RNAs can serve as prognostic biomarkers for clear cell renal cell carcinoma [PDF]

, 2021
Cheng Shan Li, Zhang Ze Lu, Da Fang, Wei Zhou, Jie Wei   +4 more
openalex   +1 more source

Cis‐regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation

Molecular Oncology, EarlyView.
The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués, Aracele Martinez‐Mendez, John Crown, Alex Eustace   +3 more
wiley   +1 more source

Comprehensive Analysis of Differentially Expressed Long Non-Coding RNA-mRNA in the Adenoma–Carcinoma Sequence of DNA Mismatch Repair Proficient Colon Cancer [PDF]

, 2020
Wenkun Li, Qian Li, Jiang Ge, Yun Wang, Nanshan Li, Yueqiong Lao, Yadan Wang, Kuiliang Liu, Chunmei Guo, Wu Lin, Guojun Jiang, Nan Wei, Canghai Wang, Hong Liu, Jing Wu   +14 more
openalex   +1 more source

Transcriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication

Molecular Oncology, EarlyView.
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice, Jose I. Lopez, Aitziber Ugalde‐Olano, Maite Zufiaurre, Ianire Astobiza, Natalia Martin‐Martin, Laura Bozal‐Basterra, Saioa Garcia‐Longarte, Amaia Zabala‐Letona, Sofia Rey, Aida Santos‐Martin, Miguel Unda, Ana Loizaga‐Iriarte, Mariona Graupera, Paolo Nuciforo, Arkaitz Carracedo, Isabel Mendizabal   +16 more
wiley   +1 more source

The H19 Long non-coding RNA in cancer initiation, progression and metastasis – a proposed unifying theory

Molecular Cancer, 2015
The imprinted oncofetal long non-coding RNA (lncRNA) H19 is expressed in the embryo, down-regulated at birth and then reappears in tumors. Its role in tumor initiation and progression has long been a subject of controversy, although accumulating data ...
E. Raveh, I. Matouk, Michal Gilon, A. Hochberg   +3 more
semanticscholar   +1 more source

Identification and validation of key long non-coding RNAs in resveratrol protect against IL-1β-treated chondrocytes via integrated bioinformatic analysis [PDF]

, 2021
Hong Yi, Wei Zhang, Shengyu Cui, Jianbo Fan, Xinhui Zhu, Wei Liu   +5 more
openalex   +1 more source

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

Molecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien   +35 more
wiley   +1 more source

CRISPRi-based radiation modifier screen identifies long non-coding RNA therapeutic targets in glioma. [PDF]

, 2020
BackgroundLong non-coding RNAs (lncRNAs) exhibit highly cell type-specific expression and function, making this class of transcript attractive for targeted cancer therapy.
Akeson, Mark, Birk, Harjus S, Gupta, Nalin, He, Daniel, Hong, Sung Jun, Horlbeck, Max A, Jain, Miten, Koontz, Mark, Lien, Brian V, Lim, Daniel A, Liu, S John, Malatesta, Martina, Monje, Michelle, Olsen, Hugh E, Pedraza, Leslie, Raleigh, David R, Saha, Parna, Seo, Kyounghee, Thombare, Shivani S, Ullian, Erik M, Weissman, Jonathan S   +20 more
core   +1 more source